JP2019512528A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512528A5 JP2019512528A5 JP2018550327A JP2018550327A JP2019512528A5 JP 2019512528 A5 JP2019512528 A5 JP 2019512528A5 JP 2018550327 A JP2018550327 A JP 2018550327A JP 2018550327 A JP2018550327 A JP 2018550327A JP 2019512528 A5 JP2019512528 A5 JP 2019512528A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- disorder
- composition according
- anxiety
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 31
- 208000019901 Anxiety disease Diseases 0.000 claims 10
- 208000020401 Depressive disease Diseases 0.000 claims 10
- 206010016256 fatigue Diseases 0.000 claims 7
- 238000002560 therapeutic procedure Methods 0.000 claims 7
- 208000007415 Anhedonia Diseases 0.000 claims 6
- 206010042458 Suicidal ideation Diseases 0.000 claims 6
- 239000013543 active substance Substances 0.000 claims 6
- 239000002552 dosage form Substances 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- 206010002869 Anxiety symptoms Diseases 0.000 claims 4
- 206010010144 Completed suicide Diseases 0.000 claims 4
- 206010041250 Social phobia Diseases 0.000 claims 4
- 208000019906 panic disease Diseases 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 206010054089 Depressive symptom Diseases 0.000 claims 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 3
- 229960003299 ketamine Drugs 0.000 claims 3
- CFBVGSWSOJBYGC-ZYHUDNBSSA-N (2r,6r)-2-amino-2-(2-chlorophenyl)-6-hydroxycyclohexan-1-one Chemical compound C=1C=CC=C(Cl)C=1[C@]1(N)CCC[C@@H](O)C1=O CFBVGSWSOJBYGC-ZYHUDNBSSA-N 0.000 claims 2
- CFBVGSWSOJBYGC-JQWIXIFHSA-N (2s,6s)-2-amino-2-(2-chlorophenyl)-6-hydroxycyclohexan-1-one Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(N)CCC[C@H](O)C1=O CFBVGSWSOJBYGC-JQWIXIFHSA-N 0.000 claims 2
- 208000008811 Agoraphobia Diseases 0.000 claims 2
- 206010033664 Panic attack Diseases 0.000 claims 2
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 2
- 208000000810 Separation Anxiety Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000000586 desensitisation Methods 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 208000024732 dysthymic disease Diseases 0.000 claims 2
- 238000011156 evaluation Methods 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 230000036651 mood Effects 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 238000001671 psychotherapy Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000025874 separation anxiety disease Diseases 0.000 claims 2
- 230000036642 wellbeing Effects 0.000 claims 2
- 206010034912 Phobia Diseases 0.000 claims 1
- 208000010513 Stupor Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000009225 cognitive behavioral therapy Methods 0.000 claims 1
- 238000009226 cognitive therapy Methods 0.000 claims 1
- 238000009228 dialectical behavior therapy Methods 0.000 claims 1
- 230000004424 eye movement Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 238000001126 phototherapy Methods 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 238000012958 reprocessing Methods 0.000 claims 1
- 230000033764 rhythmic process Effects 0.000 claims 1
- 201000001716 specific phobia Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000009897 systematic effect Effects 0.000 claims 1
- 230000002123 temporal effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662313317P | 2016-03-25 | 2016-03-25 | |
| US62/313,317 | 2016-03-25 | ||
| PCT/US2017/024238 WO2017165877A1 (en) | 2016-03-25 | 2017-03-27 | Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post traumatic stress disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019512528A JP2019512528A (ja) | 2019-05-16 |
| JP2019512528A5 true JP2019512528A5 (enExample) | 2020-05-07 |
Family
ID=58530652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018550327A Pending JP2019512528A (ja) | 2016-03-25 | 2017-03-27 | 抑うつ、不安症、快感消失症、疲労、自殺念慮、および外傷後ストレス障害の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミンおよび（２ｓ，６ｓ）−ヒドロキシノルケタミンの使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20190083420A1 (enExample) |
| EP (1) | EP3432869A1 (enExample) |
| JP (1) | JP2019512528A (enExample) |
| CN (1) | CN109475514A (enExample) |
| AU (1) | AU2017238858A1 (enExample) |
| CA (1) | CA3019012A1 (enExample) |
| WO (1) | WO2017165877A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016288188B2 (en) | 2015-06-27 | 2021-08-05 | Shenox Pharmaceuticals, Llc | Ketamine transdermal delivery system |
| US10919842B2 (en) | 2016-03-25 | 2021-02-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine |
| CN108884019A (zh) * | 2016-04-11 | 2018-11-23 | 克雷西奥生物科技有限公司 | 氘代氯胺酮衍生物 |
| US20210113493A1 (en) * | 2016-11-30 | 2021-04-22 | Philip E. Wolfson | Ketamine for the treatment of menstrually related symptoms |
| EP3505157B1 (en) | 2017-12-29 | 2021-12-08 | Celon Pharma S.A. | Dry powder ketamine composition for pulmonary administration in treatment-resistant depression |
| EP3753557B1 (en) | 2018-02-15 | 2025-11-05 | National University Corporation Chiba University | Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases |
| CN110343050B (zh) * | 2018-04-04 | 2021-09-24 | 上海键合医药科技有限公司 | 芳香类化合物及其制备方法和用途 |
| EP3813808A4 (en) | 2018-05-04 | 2022-01-26 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| WO2020237748A1 (zh) * | 2019-05-24 | 2020-12-03 | 北京大学深圳研究生院 | 一种长效化合物的制备方法 |
| KR20220097405A (ko) * | 2019-11-05 | 2022-07-07 | 클라에스 툴린 | 포유동물에서의 혹사의 예방 및/또는 치료에 사용하기 위한 4-[5-[(rac)-1-[5-(3-클로로페닐)-3-이속사졸일]에톡시]-4-메틸-4H-1,2,4-트리아졸-3-일]피리딘 |
| CN113125586B (zh) * | 2019-12-31 | 2022-05-24 | 成都百裕制药股份有限公司 | 一种1-[2-(2，4-二甲基-苯硫基)-苯基]哌嗪及其异构体的检测方法 |
| KR20230024383A (ko) | 2020-08-31 | 2023-02-20 | 선전 루이지엔 바이오테크놀로지 컴퍼니 리미티드 | 장기 작용성 및 저중독성 화합물 및 그의 제조 방법 |
| WO2022041174A1 (zh) | 2020-08-31 | 2022-03-03 | 深圳瑞健生物科技有限公司 | 一种长效低成瘾性hnk衍生物及其制备方法 |
| CN112521357B (zh) * | 2020-08-31 | 2021-10-08 | 深圳瑞健生物科技有限公司 | 一种长效低成瘾性hnk衍生物及其制备方法 |
| CN112516130B (zh) * | 2020-08-31 | 2022-01-04 | 深圳瑞健生物科技有限公司 | 一种长效低成瘾性化合物在制备药物中的应用 |
| CN114524737B (zh) * | 2020-11-23 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 一种取代的环己酮类化合物 |
| CN114947839B (zh) * | 2022-05-27 | 2025-12-02 | 华东师范大学 | 大脑调控的训练方法、装置及电子设备 |
| CN120736994B (zh) * | 2025-01-26 | 2025-11-18 | 上海东西智荟生物医药有限公司 | 氯胺酮衍生物及其在精神疾病的治疗中的用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6296985B2 (ja) * | 2011-10-14 | 2018-03-20 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | うつ病及び神経障害性疼痛の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミン、（ｓ）−デヒドロノルケタミン及び他の（ｒ，ｓ）−ケタミンの立体異性デヒドロ及びヒドロキシル化代謝生成物の使用 |
| WO2014020155A1 (en) * | 2012-08-02 | 2014-02-06 | Clinpharm Reform Gmbh | Oral transmucosal adminstration forms of s-ketamine |
-
2017
- 2017-03-27 JP JP2018550327A patent/JP2019512528A/ja active Pending
- 2017-03-27 US US16/088,294 patent/US20190083420A1/en not_active Abandoned
- 2017-03-27 EP EP17716697.2A patent/EP3432869A1/en not_active Withdrawn
- 2017-03-27 WO PCT/US2017/024238 patent/WO2017165877A1/en not_active Ceased
- 2017-03-27 CN CN201780029039.8A patent/CN109475514A/zh active Pending
- 2017-03-27 AU AU2017238858A patent/AU2017238858A1/en not_active Abandoned
- 2017-03-27 CA CA3019012A patent/CA3019012A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512528A5 (enExample) | ||
| Gong et al. | Clinical manifestations of Parkinson disease and the onset of rapid eye movement sleep behavior disorder | |
| EP3043785B1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| JP2020528075A5 (enExample) | ||
| PH12014500472A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| PH12014500239A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| PH12014500371A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| Lehman | Epidemiology of neurodegeneration in American-style professional football players | |
| BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
| BR112015010396A2 (pt) | terapia de combinação | |
| JP2014511374A5 (enExample) | ||
| WO2014058979A3 (en) | Laquinimod for reducing thalamic damage in multiple sclerosis | |
| ME01629B (me) | Upotreba 3,11 b-cis-dihidrotetrabenazina za tretman simptoma huntington-ove bolesti | |
| Devnani et al. | Management of REM sleep behavior disorder: an evidence based review | |
| JP2018526345A5 (enExample) | ||
| Alamy et al. | Escitalopram in specific phobia: results of a placebo-controlled pilot trial | |
| Clark et al. | A hypnic hypothesis of Alzheimer's disease | |
| Simnani et al. | Impact of COVID-19 on brain and psychological health, its possible mechanisms, and coping strategies | |
| Ebrahim et al. | REM sleep behavior disorder–psychiatric presentations: a case series from the United Kingdom | |
| CN107456572B (zh) | 完全羧化骨钙素在制备快速抗抑郁药中的应用 | |
| Tang et al. | Topiramate in traumatic brain injury: adverse effects on cognitive function | |
| Habermeyer et al. | Psychosis in a case of schizophrenia and Parkinson’s disease | |
| McLeod et al. | 30 (11A) The concussion quality of life scale-youth validates and complements the post-concussion symptom inventory on days 3 and 10 post-concussion | |
| Mills et al. | Sports dental trauma for children and adolescents: unique considerations |